Lysosomal sequestration of anticancer therapeutics lowers their cytotoxic potential, reduces drug availability at target sites, and contributes to cancer resistance. Only recently has it been shown that lysosomal sequestration of weak base drugs induces lysosomal biogenesis mediated by activation of transcription factor EB (TFEB) which, in turn, enhances their accumulation capacity, thereby increasing resistance to these drugs. Here, we addressed the question of whether lysosomal biogenesis is the only mechanism that increases lysosomal sequestration capacity. We found that lysosomal sequestration of some tyrosine kinase inhibitors (TKIs), gefitinib (GF) and imatinib (IM), induced expansion of the lysosomal compartment. However, an expression analysis of lysosomal genes, including lysosome-associated membrane proteins 1, 2 (LAMP1, LAMP2), vacuolar ATPase subunit B2 (ATP6V1B2), acid phosphatase (ACP), and galactosidase beta (GLB) controlled by TFEB, did not reveal increased expression. Instead, we found that both studied TKIs, GF and IM, induced lysosomal fusion which was dependent on nicotinic acid adenine dinucleotide phosphate (NAADP) mediated Ca2+signaling. A theoretical analysis revealed that lysosomal fusion is sufficient to explain the enlargement of lysosomal sequestration capacity. In conclusion, we demonstrated that extracellular TKIs, GF and IM, induced NAADP/Ca2+ mediated lysosomal fusion, leading to enlargement of the lysosomal compartment with significantly increased sequestration capacity for these drugs without apparent lysosomal biogenesis.

Department of Anatomy Faculty of Medicine and Dentistry Palacky University Olomouc Hnevotinska 3 77515 Olomouc Czech Republic

Zobrazit více v PubMed

Appelmans F., Wattiaux R., De Duve C. Tissue fractionation studies. 5. The association of acid phosphatase with a special class of cytoplasmic granules in rat liver. Biochem. J. 1955;59:438–445. doi: 10.1042/bj0590438. PubMed DOI PMC

De Duve C. Lysosomes, a new group of cytoplasmic particles. In: Hayashi T., editor. Subcellular Particles. The Ronald Press Co.; New York, NY, USA: 1959. pp. 128–159.

Saftig P., Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: Trafficking meets function. Nat. Rev. Mol. Cell Biol. 2009;10:623–635. doi: 10.1038/nrm2745. PubMed DOI

Lűllmann-Rauch R. History and morphology of the lysosome. In: Saftig P., editor. Lysosomes. Springer; New York, NY, USA: 2005.

Boya P. Lysosomal function and dysfunction: Mechanism and disease. Antioxid. Redox Signal. 2012;17:766–774. doi: 10.1089/ars.2011.4405. PubMed DOI

Appelqvist H., Wäster P., Kågedal K., Öllinger K. The lysosome: From waste bag to potential therapeutic target. J. Mol. Cell Biol. 2013;5:214–226. doi: 10.1093/jmcb/mjt022. PubMed DOI

Perera R.M., Zoncu R. The lysosome as a regulatory hub. Annu. Rev. Cell Dev. Biol. 2016;32:223–253. doi: 10.1146/annurev-cellbio-111315-125125. PubMed DOI PMC

Inpanathan S., Botelho R.J. The lysosome signaling platform: Adapting with the times. Front. Cell Dev. Biol. 2019;7:113. doi: 10.3389/fcell.2019.00113. PubMed DOI PMC

Futerman A.H., van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 2004;5:554–565. doi: 10.1038/nrm1423. PubMed DOI

Larsen A.K., Escargueil A.E., Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther. 2000;85:217–229. doi: 10.1016/S0163-7258(99)00073-X. PubMed DOI

Duvvuri M., Krise J.P. Intracellular drug sequestration events associated with the emergence of multidrug resistance: A mechanistic review. Front. Biosci. 2005;10:1499–1509. doi: 10.2741/1634. PubMed DOI

Zhitomirsky B., Assaraf Y.G. Lysosomes as mediators of drug resistance in cancer. Drug Resist. Updates. 2016;24:23–33. doi: 10.1016/j.drup.2015.11.004. PubMed DOI

De Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., van Hoof F. Commentary. Lysosomotropic agents. Biochem. Pharmacol. 1974;23:2495–2531. doi: 10.1016/0006-2952(74)90174-9. PubMed DOI

MacIntyre A.C., Cutler D.J. The potential role of lysosomes in tissue distribution of weak bases. Biopharm. Drug Dispos. 1988;9:513–526. doi: 10.1002/bod.2510090602. PubMed DOI

Shiraishi N., Akiyama S., Kobayashi M., Kuwano M. Lysosomotropic agents reverse multiple drug resistance in human cancer cells. Cancer Lett. 1986;30:251–259. doi: 10.1016/0304-3835(86)90049-2. PubMed DOI

Hindenburg A.A., Gervasoni J.E., Jr., Krishna S., Stewart V.J., Rosado M., Lutzky J., Bhalla K., Baker M.A., Taub R.N. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res. 1989;49:4607–4614. PubMed

Gervasoni J.E., Jr., Fields S.Z., Krishna S., Baker M.A., Rosado M., Thuraisamy K., Hindenburg A.A., Taub R.N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 1991;51:4955–4963. PubMed

Hurwitz S.J., Terashima M., Mizunuma N., Slapak C.A. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: Participation of lysosomes. Blood. 1997;89:3745–3754. doi: 10.1182/blood.V89.10.3745. PubMed DOI

Chapuy B., Panse M., Radunski U., Koch R., Wenzel D., Inagaki N., Haase D., Truemper L., Wulf G.G. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica. 2009;94:1528–1536. doi: 10.3324/haematol.2009.008631. PubMed DOI PMC

Gotink K.J., Broxterman H.J., Labots M., de Haas R.R., Dekker H., Honeywell R.J., Rudek M.A., Beerepoot L.V., Musters R.J., Jansen G., et al. Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance. Clin. Cancer Res. 2011;17:7337–7346. doi: 10.1158/1078-0432.CCR-11-1667. PubMed DOI PMC

Colombo F., Trombetta E., Cetrangolo P., Maggioni M., Razini P., De Santis F., Torrente Y., Prati D., Torresani E., Porretti L. Giant lysosomes as a chemotherapy resistance mechanism in hepatocellular carcinoma cells. PLoS ONE. 2014;9:e114787. doi: 10.1371/journal.pone.0114787. PubMed DOI PMC

Giuliano S., Cormerais Y., Dufies M., Grépin R., Colosetti P., Belaid A., Parola J., Martin A., Lacas-Gervais S., Mazure N.M., et al. Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux. Autophagy. 2015;11:1891–1904. doi: 10.1080/15548627.2015.1085742. PubMed DOI PMC

Gotink K.J., Rovithi M., de Haas R.R., Honeywell R.J., Dekker H., Poel D., Azijli K., Peters G.J., Broxterman H.J., Verheul H.M. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell. Oncol. 2015;38:119–129. doi: 10.1007/s13402-015-0218-8. PubMed DOI PMC

Zhitomirsky B., Assaraf Y.G. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget. 2015;6:1143–1156. doi: 10.18632/oncotarget.2732. PubMed DOI PMC

Sardiello M., Palmieri M., di Ronza A., Medina D.L., Valenza M., Gennarino V.A., Di Malta C., Donaudy F., Embrione V., Polishchuk R.S., et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325:473–477. doi: 10.1126/science.1174447. PubMed DOI

Settembre C., Fraldi A., Medina D.L., Ballabio A. Signals from the lysosome: A control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 2013;14:283–296. doi: 10.1038/nrm3565. PubMed DOI PMC

Mlejnek P., Novak O., Dolezel P. A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells. Talanta. 2011;83:1466–1471. doi: 10.1016/j.talanta.2010.11.028. PubMed DOI

Krumpochova P., Kocurova A., Dolezel P., Mlejnek P. Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype. J. Chromatogr. B. 2011;879:1875–1880. doi: 10.1016/j.jchromb.2011.05.008. PubMed DOI

Kosztyu P., Bukvova R., Dolezel P., Mlejnek P. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. Chem. Biol. Interact. 2014;219:203–210. doi: 10.1016/j.cbi.2014.06.009. PubMed DOI

Burger H., den Dekker A.T., Segeletz S., Boersma A.W., de Bruijn P., Debiec-Rychter M., Taguchi T., Sleijfer S., Sparreboom A., Mathijssen R.H., et al. Lysosomal sequestration determines intracellular imatinib levels. Mol. Pharmacol. 2015;88:477–487. doi: 10.1124/mol.114.097451. PubMed DOI

Ruzickova E., Skoupa N., Dolezel P., Smith D.A., Mlejnek P. The lysosomal sequestration of tyrosine kinase inhibitors and drug resistance. Biomolecules. 2019;9:675. doi: 10.3390/biom9110675. PubMed DOI PMC

Frydrych I., Mlejnek P. Serine protease inhibitors N-alpha-tosyl-L-lysinyl-chloromethylketone (TLCK) and N-tosyl-L-phenylalaninyl-chloromethylketone (TPCK) do not inhibit caspase-3 and caspase-7 processing in cells exposed to pro-apoptotic inducing stimuli. J. Cell. Biochem. 2008;105:1501–1506. doi: 10.1002/jcb.21971. PubMed DOI

Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. PubMed DOI

Mlejnek P., Kosztyu P., Dolezel P., Kimura Y., Cizkova K., Ruzickova E. Estimation of ABCB1 concentration in plasma membrane. J. Cell. Biochem. 2019;120:18406–18414. doi: 10.1002/jcb.29157. PubMed DOI

Jain P., Kantarjian H., Alattar M.L., Jabbour E., Sasaki K., Nogueras Gonzalez G., Dellasala S., Pierce S., Verstovsek S., Wierda W., et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: Retrospective analysis of patient data from five clinical trials. Lancet Haematol. 2015;2:e118–e128. doi: 10.1016/S2352-3026(15)00021-6. PubMed DOI PMC

Cioccio J., Claxton D. Therapy of acute myeloid leukemia: Therapeutic targeting of tyrosine kinases. Expert Opin. Investig. Drugs. 2019;28:337–349. doi: 10.1080/13543784.2019.1584610. PubMed DOI

Lu S., Sung T., Lin N., Abraham R.T., Jessen B.A. Lysosomal adaptation: How cells respond to lysosomotropic compounds. PLoS ONE. 2017;12:e0173771. doi: 10.1371/journal.pone.0173771. PubMed DOI PMC

Zhitomirsky B., Assaraf Y.G. Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis. Oncotarget. 2017;8:45117–45132. doi: 10.18632/oncotarget.15155. PubMed DOI PMC

Medina D.L., Fraldi A., Bouche V., Annunziata F., Mansueto G., Spampanato C., Puri C., Pignata A., Martina J.A., Sardiello M., et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev. Cell. 2011;21:421–430. doi: 10.1016/j.devcel.2011.07.016. PubMed DOI PMC

Roczniak-Ferguson A., Petit C.S., Froehlich F., Qian S., Ky J., Angarola B., Walther T.C., Ferguson S.M. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci. Signal. 2012;5:ra42. doi: 10.1126/scisignal.2002790. PubMed DOI PMC

Pryor P.R., Mullock B.M., Bright N.A., Gray S.R., Luzio J.P. The role of intraorganellar Ca(2+) in late endosome-lysosome heterotypic fusion and in the reformation of lysosomes from hybrid organelles. J. Cell Biol. 2000;149:1053–1062. doi: 10.1083/jcb.149.5.1053. PubMed DOI PMC

Luzio J.P., Pryor P.R., Bright N.A. Lysosomes: Fusion and function. Nat. Rev. Mol. Cell Biol. 2007;8:622–632. doi: 10.1038/nrm2217. PubMed DOI

Galione A. NAADP Receptors. Cold Spring Harb. Perspect. Biol. 2019;11:a035071. doi: 10.1101/cshperspect.a035071. PubMed DOI PMC

What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?